EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

Objective: To compare the combination of a MEK inhibitor (pimasertib) and a PI3K inhibitor (SAR245409) to pimasertib alone in recurrent unresectable borderline/low malignant potential (LMP) or low-grade serous ovarian carcinoma (LGSOC), determining whether combination is superior.

Methods: Patients with previously treated, recurrent LMP or LGSOC with measurable disease received either combination of pimasertib (60 mg daily) + SAR245409 (SAR) (70 mg daily) or pimasertib alone (60 mg BID) until progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR) by RECIST 1.

[Course of pregnancy, delivery in adolescents treated in I Clinical Unit of Obstetrics and Gynecology in Bytom (1997-2001)].

Objectives: The subject of our analysis was pregnancy, delivery and perinatal outcome in adolescent girls treated in I Clinical Unit of Obstetrics and Gynecology in Bytom in the period 1997-2001.

Material And Methods: Our materials were 164 pregnant adolescent girls aged 14-18. Course of pregnancy, type of delivery, perinatal outcome and the recourse to cesarean section were retrospectively analysed in our study.

[Ovarian tumors in pregnancy].

Objectives: The presence of adnexal tumours in pregnancy is a significant problem for obstetricians requiring quick diagnosis and operation.

Materials And Methods: The paper presents 22 cases of ovarian tumours diagnosed and treated during pregnancy. In 12 cases laparoscopical cystectomies were performed, in 10 cases laparotomies were done.